-
Medtronic, Stryker, Weigao... the latest layout announced
Time of Update: 2021-04-19
Therefore, in the face of the inevitable collection of orthopedics, domestic and foreign orthopedic companies have frequently made efforts to accelerate the diversified industrial layout.
-
2020 global pharmaceutical CEO salary competition: Johnson & Johnson approaches 200 million yuan
Time of Update: 2021-04-18
html" target="_blank">The medical representative salary survey officially announced that the median is less than 6000 yuan (2020-12-30)pharmnet.
-
The Rehabilitation Branch of the Chinese Anti-Cancer Association · MDT Consultation Center launched in U.S.-China Ai Rui to start tumor diagnosis
Time of Update: 2021-04-13
pursued. As a professional organization for the diagnosis and treatment of cancer patients, the Rehabilitation Branch of the Chinese Anti-Cancer Association has been committed to improving the status quo of the diagnosis
-
To assist the public in scientific anti-aging, Yiling Pharmaceutical launched the "Eight Kidney Essence Anti-aging Action"
Time of Update: 2021-04-13
Health Commission, up to 75% of the elderly suffer from one or more chronic diseases, and there are about 40 million disabled and partially disabled elderly people. The 2017 epidemiological survey showed that the prevalence
-
Inject innovation power into a healthy China
Time of Update: 2021-04-13
/> Drug innovation and research are undoubtedly a healthy China. An important part of the strategy, it is not only essential for improving the level of disease prevention and treatment and improving people’s health, but also for promoting
-
RDPAC Innovation Leads Health China High-end Interview "Drug Quality and Safety"
Time of Update: 2021-03-30
="vertical-align: inherit;"> The high-end interview series of "Innovation Leads Healthy China" by the Pharmaceutical Research and Development Industry Committee of the China Association of Foreign Investment Enterprises (RDPAC) was officially released
-
RDPAC Innovation Leads the High-end Interview "Drug Accessibility" in Health China
Time of Update: 2021-03-30
The high-end interview series of "Innovation Leads Healthy China" by the Pharmaceutical Research and Development Industry Committee (RDPAC) of the China Association of Enterprises with Foreign Investment was officially released on the occasion of the two sessions.
-
Finance Weekly | 3.12-3.18 National Medical and Health Industry Financing Inventory
Time of Update: 2021-03-29
infectious disease project of Tengshengbo medicine pipeline, as well as the company's central nervous system disease project.
><font style
-
Two injections of Sichuan Creed Pharmaceuticals continue to enter administrative approval
Time of Update: 2021-03-29
Recently, the Sodium Valproate Injection and Micuronium Chloride Injection, which were reported for production by Sichuan Creed Pharmaceuticals under the new registration classification, have entered the administrative examination and approval stage.
-
Can you increase the amount with medical insurance?
Time of Update: 2021-03-29
In 2016, a total of 3 products were successfully negotiated by the Health and Family Planning Commission, and successively added to the medical insurance in various places, and only officially entered the medical insurance catalog in 2017;
-
East Asia Pharmaceuticals: Subsidiary cefaclor API passed Japan PMDA GMP certification
Time of Update: 2021-03-29
On March 24, 2021, Toho Pharmaceutical received the "Notification of Drug Suitability Survey Results" issued by PMDA, confirming that Toho Pharmaceutical's cefaclor API passed the Japanese GMP certification.
-
India discovers double mutation new mutated new coronavirus
Time of Update: 2021-03-29
The strain has double mutations, which may weaken the immune effect.
-
Kelun RET inhibitor reaches overseas authorization
Time of Update: 2021-03-29
A400 R & D project is the Cologne Great proprietary small molecule selective targeting RET kinase inhibitor formulation, the project was completed in March 2021 formally submitted an IND to the NMPA, layout and has a number of international patents.
-
"Pharmaceutical Speed Reading Society" Hengrui Medicine's anti-tumor drug review Dongyang Sunshine Entacapone Tablets Approved
Time of Update: 2021-03-29
[March 25, 2021 / Medical Information List] Hengrui Medicine anticancer drugs through assessment; East Sunshine entacapone tablets granted; India found new variation of the double mutant virus .
-
Renhe Pharmaceuticals Entecavir Tablets Obtained Drug Registration Certificate
Time of Update: 2021-03-29
="vertical-align: inherit;">
On March 25, Renhe Pharmaceutical announced that its subsidiary Jiangxi Pharmaceutical has recently received the "Drug Registration Certificate" for Entecavir tablets approved and issued by the State Drug Administration. <br
-
The first phase III study of Bristol-Myers Squibb PD-1+LAG-3 combination therapy is successful
Time of Update: 2021-03-29
RELATIVITY-047 study, a fixed-dose relatlimab (LAG-3 monoclonal antibody) + Opdivo (PD-1 monoclonal antibody) combination therapy for the first-line treatment of metastatic or unresectable melanin Compared with the use of Opdivo alone, tumors can
-
Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-03-29
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.
-
AbbVie accused competitor of stealing Xiumile trade secrets
Time of Update: 2021-03-29
When AbbVie contacted Alvogen about the alleged theft, the biosimilar manufacturer did not deny that Rongzan Ho was developing a generic version of its Humira.
-
The person in charge of quality was fined 100,000 yuan for falsifying the license
Time of Update: 2021-03-29
style="vertical-align: inherit;">
2. The "Production Suspension Notice", "Production Suspension Plan", "Production Quality Management Self-inspection Report", and "Notice on Removal of Zhou Ze as Quality Manager and Quality Authorized Person
-
Hutchison Pharma enters into an agreement to sell non-core non-prescription drug joint ventures for US$169 million
Time of Update: 2021-03-29
On March 24, Hutchison Medicine announced that it had reached a US$169 million transaction agreement with GL Mountrose Investment Two Limited, which is controlled and managed by Telford Capital.
